EA202190463A1 - Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов - Google Patents
Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторовInfo
- Publication number
- EA202190463A1 EA202190463A1 EA202190463A EA202190463A EA202190463A1 EA 202190463 A1 EA202190463 A1 EA 202190463A1 EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A1 EA202190463 A1 EA 202190463A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- disease
- ccr3
- function
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Предложены способы облегчения нейродегенеративного заболевания с применением CCR3-модулирующих агентов. Предложенные способы включают введение субъекту терапевтически эффективного количества CCR3-модулирующего агента с сопутствующим улучшением познавательной функции, двигательной функции или другой функции, нарушенной вследствие нейродегенеративного заболевания. Когнитивные и двигательные заболевания, при которых когнитивная функция может быть улучшена способами по данному изобретению, включают болезнь Альцгеймера, болезнь Паркинсона, лобно-височную деменцию, болезнь Хантингтона, амиотрофический боковой склероз, рассеянный склероз, глаукому, миотоническую дистрофию, сосудистую деменцию, прогрессирующий надъядерный паралич.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737017P | 2018-09-26 | 2018-09-26 | |
PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190463A1 true EA202190463A1 (ru) | 2021-06-29 |
Family
ID=69953286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190463A EA202190463A1 (ru) | 2018-09-26 | 2019-09-25 | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3856195A4 (ru) |
JP (1) | JP7528065B2 (ru) |
KR (1) | KR20210065950A (ru) |
CN (1) | CN112789044A (ru) |
AU (1) | AU2019346456A1 (ru) |
BR (1) | BR112021004938A2 (ru) |
CA (1) | CA3111433A1 (ru) |
CL (1) | CL2021000724A1 (ru) |
CO (1) | CO2021003713A2 (ru) |
EA (1) | EA202190463A1 (ru) |
IL (1) | IL281578A (ru) |
MA (1) | MA53743A (ru) |
MX (1) | MX2021002967A (ru) |
SG (1) | SG11202102105VA (ru) |
TW (1) | TW202027752A (ru) |
WO (1) | WO2020069008A1 (ru) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
PE20150925A1 (es) | 2009-04-22 | 2015-06-14 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
CN110650740A (zh) * | 2017-04-05 | 2020-01-03 | 万能溶剂有限公司 | 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物 |
BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
-
2019
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210065950A (ko) | 2021-06-04 |
CA3111433A1 (en) | 2020-04-02 |
JP7528065B2 (ja) | 2024-08-05 |
JP2022502441A (ja) | 2022-01-11 |
MX2021002967A (es) | 2021-08-11 |
BR112021004938A2 (pt) | 2021-06-01 |
CL2021000724A1 (es) | 2021-10-15 |
MA53743A (fr) | 2022-01-05 |
IL281578A (en) | 2021-05-31 |
TW202027752A (zh) | 2020-08-01 |
WO2020069008A1 (en) | 2020-04-02 |
EP3856195A1 (en) | 2021-08-04 |
SG11202102105VA (en) | 2021-04-29 |
EP3856195A4 (en) | 2022-06-22 |
CN112789044A (zh) | 2021-05-11 |
AU2019346456A1 (en) | 2021-04-15 |
CO2021003713A2 (es) | 2021-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011988A (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3. | |
WO2018015573A3 (en) | Trem2 cleavage modulators and uses thereof | |
PH12018502028A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
MX2019006645A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
EA201991755A1 (ru) | Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков | |
EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
JP2019524822A5 (ru) | ||
MX2023012694A (es) | 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas. | |
PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
DK2091942T3 (da) | Substituerede pyrazinderivater til anvendelse som en medicin | |
EA202190463A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
WO2020092102A3 (en) | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor | |
EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
PA8608601A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
BR112022011810A2 (pt) | Compostos inibidores de oga | |
MA54630B1 (fr) | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives | |
NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
MX2021007551A (es) | Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas. | |
MX2017012239A (es) | Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas. |